Madrigal Pharmaceuticals, Inc. (MDGL) Stock Forecast
MDGL analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.74 / 5 from 19 analysts
- Price target
- $685.78 average of analyst targets
- Upside to target
- +52.5% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $1.00
- 52-week range
- $412.35 – $602.83
MDGL analyst ratings
19 analystsNumber of analysts at each rating.
MDGL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MDGL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.09 | −$1.38 | −$0.56 | −$4.96 | +78.0% | 4 |
| Current fiscal year (2026) | −$6.49 | −$7.38 | −$4.91 | −$12.73 | +49.0% | 4 |
| Next fiscal year (2027) | $9.62 | $7.01 | $12.84 | −$6.49 | +248.2% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MDGL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $406.3M | $384.7M | $425.0M | +41.4% | 17 |
| Current fiscal year (2026) | $1.53B | $1.48B | $1.58B | +59.6% | 18 |
| Next fiscal year (2027) | $2.12B | $1.93B | $2.34B | +38.8% | 17 |
MDGL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MDGL revenue: reported and forecast
MDGL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.03 | −$1.09 | −$1.09 | −$1.09 | −$1.09 | +5.2% | 0 up · 0 down |
| Current fiscal year (2026) | −$6.52 | −$6.49 | −$6.49 | −$6.49 | −$6.49 | −0.5% | 0 up · 0 down |
| Next fiscal year (2027) | $12.38 | $9.62 | $9.62 | $9.62 | $9.62 | −22.3% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MDGL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MDGL beat in 7 of 12.
What analysts expect from MDGL
19 analysts cover Madrigal Pharmaceuticals; their consensus rating is strong buy (4.74 on a 1–5 scale, where 5 is a strong buy). The average price target is $685.78, 52.5% above the latest close of $449.74. Analysts expect earnings of −$6.49 per share for 2026, +49.0% from a year earlier. For 2027 the average estimate is $9.62 per share on revenue of $2.1 billion. Madrigal Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: MDGL income statement, MDGL key metrics, MDGL chart. See the MDGL stock overview for the latest quote and news.
MDGL forecast FAQ
What is Madrigal Pharmaceuticals's price target?
The average analyst price target for Madrigal Pharmaceuticals is $685.78, 52.5% above the latest close of $449.74.
Is Madrigal Pharmaceuticals a buy, hold or sell?
Of 19 analysts covering Madrigal Pharmaceuticals, 15 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Madrigal Pharmaceuticals's EPS forecast?
Analysts forecast −$6.49 per share for 2026 (range −$7.38 to −$4.91); for 2027 the estimate is $9.62.
What is Madrigal Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.5 billion, growth of 59.6%; for 2027 it is $2.1 billion.
When does Madrigal Pharmaceuticals report earnings?
Madrigal Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $1.00.
Does Madrigal Pharmaceuticals usually beat earnings estimates?
Madrigal Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.